Short-course rifampin plus isoniazid is comparable to long-term isoniazid for latent tuberculosis {#cesec10}
=================================================================================================

ST LOUIS (MD Consult)---A short course of combined rifampin and isoniazid is as effective and safe as long-term isoniazid monotherapy for patients with latent tuberculosis infection, according to a new meta-analysis. The shorter course, however, may improve patient compliance with therapy.

Dr Javier Ena of Marina Baixa Hospital in Villajoyosa and Dr and Victoria Valls of Universidad Miguel Hernandez in Alicante, Spain, discuss their findings in the March 1 *Clinical Infectious Diseases*.

The authors searched for published (MEDLINE, Cochrane Library, and EMBASE databases) and unpublished (Cambridge Scientific Abstracts Internet database, Conference Papers Index, AIDS and Cancer Research Abstracts, and ClinicalTrials.gov) trials in which patients with latent tuberculosis were randomized to receive either 3 months of combined rifampin plus isoniazid or 6 to 12 months of isoniazid monotherapy.

They identified 5 trials involving 1926 adults; about 72% of the patients had human immunodeficiency virus infection. Mean follow up ranged from 13 to 37 months.

The proportion of patients who developed active tuberculosis was virtually identical in the combined treatment and monotherapy groups (4.2 vs. 4.1%, respectively), with no significant heterogeneity between the groups.

The proportion of patients with severe adverse events was also similar for the 2 groups (4.9 vs. 4.8%, respectively), although statistically significant heterogeneity was detected. However, subanalysis of the 2 high-quality, blinded trials (which included 74% of subjects) indicated that the 2 regimens were equally safe.

Of the 3 trials (including 72% of subjects) that reported on mortality, death rates did not differ significantly between the combined treatment and monotherapy groups (9.5 vs. 10.4%), with no significant heterogeneity between the groups.

Thus, in terms of efficacy, safety, and mortality, 3 months of combined rifampin plus isoniazid is comparable with standard isoniazid therapy for preventing active tuberculosis. The shorter course may have an advantage in terms of patient acceptance, because adherence to treatment (reported in 4 trials) was as good as or better with combination therapy than with standard monotherapy.

*Clin Infect Dis* 2005;**40**:670--6.

Risk of human-to-human transmission of monkeypox virus to HCWs is low {#cesec20}
=====================================================================

ST LOUIS (MD Consult)---The 2003 outbreak of human monkeypox virus in the United States was associated with exposure to infected prairie dogs. Exposure to humans infected with monkeypox, however, does not pose a major risk of transmission for health care workers (HCWs), according to a new study.

Dr Aaron T. Fleischauer and colleagues of the Centers for Disease Control and Prevention in Atlanta and other institutions discuss their findings in the March 1 *Clinical Infectious Diseases*.

The authors identified 81 HCWs who came within 2 month of 3 patients with confirmed monkeypox infection. Of these, 57 (70%) completed a questionnaire and provided serum samples for testing.

In all, 40 HCWs (70%) had at least 1 unprotected exposure to a case patient, with a range of up to 68 exposures, each lasting up to 75 min. However, none of them reported signs or symptoms that were consistent with monkeypox infection.

Serologic evidence of recent orthopoxvirus infection was found in 1 exposed HCW (2%). This subject, however, had been vaccinated for smallpox within the past year and was exposed to a case patient 1 time while wearing gloves. Still, it cannot be determined whether the positive findings for anti-orthopoxvirus immunoglobulin M were caused by vaccination against smallpox or exposure to monkeypox.

Given the lack of signs or symptoms of monkeypox in these exposed HCWs and the number and duration of contacts that they had with the infected patients, the authors conclude that the transmission of monkeypox is likely a rare event in the health care setting.

*Clin Infect Dis* 2005;**40**:689--94.

Study identified risk factors for hematogenous seeding with IV catheters {#cesec30}
========================================================================

ST LOUIS (MD Consult)---Four risk factors can help physicians estimate the risk of hematogenous bacterial seeding after intravascular-catheter-associated *Staphylococcus aureus* bacteraemia, according to the March 1 *Clinical Infectious Diseases.*

Dr Vance G. Fowler, Jr, and colleagues of Duke University Medical Center in Durham, NC, and other institutions prospectively studied 324 patients who developed intravascular-catheter-associated *S. aureus* bacteraemia over a 91-month period.

Hematogenous complications (septic arthritis, vertebral osteomyelitis, or endocarditis) occurred in 42 of these patients (13%).

Multivariate analyses identified 4 factors that were significantly and independently associated with hematogenous seeding:1.dependence on hemodialysis (odds ratio \[OR\], 72);2.presence of long-term intravascular catheter or non-catheter prosthesis (OR, 4.2);3.infection with methicillin-resistant *S. aureus* (OR, 2.3); and4.duration of symptoms (OR, 1.15 for each day symptoms were present before diagnosis).

These findings underscore the importance of vigilance and prompt catheter removal for preventing the hematogenous seeding of *S. aureus* bacteraemia.

*Clin Infect Dis* 2005;**40**:695--703.

Pioglitazone improves metabolic syndrome induced by HAART {#cesec40}
=========================================================

ST LOUIS (MD Consult)---Many patients with human immunodeficiency virus (HIV) infection develop metabolic syndrome while taking highly active antiretroviral therapy (HAART). Pioglitazone can improve insulin resistance, triglyceride levels, and blood pressure in patients with HAART-induced metabolic syndrome, according to the March 1 *Clinical Infectious Diseases.*

Dr Alina Gavrila and colleagues of Beth Israel Deaconess Medical Center in Boston, Mass, studied 14 adults with HIV (93% men; mean age, 48 years) who had taken \>6 months of antiretroviral therapy. All had developed insulin resistance, impaired glucose tolerance, or type 2 diabetes mellitus and elevated fasting triglyceride and/or low-density lipoprotein cholesterol levels.

Patients received 12 months of therapy with either placebo alone (*n*=4), placebo plus pioglitazone (*n*=4), placebo plus fenofibrate (*n*=3), or both active drugs (*n*=3).

At 12 months, changes in insulin resistance, lipid profiles, and other parameters had not changed significantly in the patients taking fenofibrate as compared with those taking placebo. These data argue against the effectiveness of fenofibrate for treating HAART-induced metabolic syndrome.

The patients taking pioglitazone, however, had significant improvements in insulin resistance, with a mean HOMA-IR index of 8.9 at baseline vs. 5.1 at 12 months and fasting insulin levels of 21.7 vs. 14.5 μIU/ml. Mean adiponectin levels also increased significantly in the pioglitazone group (from 2.6 to 7.4 μg/ml).

Triglyceride levels decreased significantly with pioglitazone (from 597.9 to 433.6 mg/dl), although low-density lipoprotein cholesterol levels continued to rise (from 109.1 to 173.9 mg/dl).

Also, systolic blood pressure improved by about 10% (from 140.1 to 126.0 mmHg), and diastolic blood pressure improved, too (from 80.7 to 75.3 mmHg).

These data show that pioglitazone is effective for treating HAART-induced metabolic syndrome and that it may have more favorable effects on blood pressure than rosiglitazone.

*Clin Infect Dis* 2005;**40**:745--9.

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection {#cesec50}
=====================================================================================================

**AUTHORS:** The rgp120 HIV Vaccine Study Group

**Background:** A vaccine is needed to prevent human immunodeficiency virus type 1 (HIV-1) infection.

**Methods:** A double-blind, randomized trial of a recombinant HIV-1 envelope glycoprotein subunit (rgp120) vaccine was conducted among men who have sex with men and among women at high risk for heterosexual transmission of HIV-1. Volunteers received 7 injections of either vaccine or placebo (ratio, 2:1) over 30 months. The primary end point was HIV-1 seroconversion over 36 months.

**Results:** A total of 5403 volunteers (5095 men and 308 women) were evaluated. The vaccine did not prevent HIV-1 acquisition: infection rates were 6.7% in 3598 vaccines and 7.0% in 1805 placebo recipients; vaccine efficacy (VE) was estimated as 6% (95% confidence interval, −17 to 24%). There were no significant differences in viral loads, rates of antiretroviral-therapy initiation, or the genetic characteristics of the infecting HIV-1 strains between treatment arms. Exploratory subgroup analyses showed non-significant trends toward efficacy in preventing infection in the highest risk (VE, 43%; *n*=247) and non-white (VE, 47%; *n*=914) volunteers (*P*=.10, adjusted for multiple subgroup comparisons).

**Conclusions:** There was no overall protective effect. The efficacy trends in subgroups may provide clues for the development of effective immunization approaches.

*J Infect Dis* 2005;**191**(5):654--65.
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Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial {#cesec60}
================================================================================================================================================================

**AUTHORS:** P.B. Gilbert, M.L. Peterson, D. Follmann, M.G. Hudgens, D.P. Francis, M. Gurwith, W.L. Heyward, D.V. Jobes, V. Popovic, S.G. Self, F. Sinangil, D. Burke, P.W. Berman

**Background:** An objective of the first efficacy trial of a candidate vaccine containing recombinant human immunodeficiency virus (HIV) type 1 envelope glycoprotein 120 (rgp120) antigens was to assess correlations between antibody responses to rgp120 and the incidence of HIV-1 infection.

**Methods:** Within the randomized trial (for vaccines, *n*=3598; for placebo recipients, *n*=1805), binding and neutralizing antibody responses to rgp120 were quantitated. A case-cohort design was used to study correlations between antibody levels and HIV-1 incidence.

**Results:** Peak antibody levels were significantly inversely correlated with HIV-1 incidence. The relative risk (RR) of infection was 0.63 (95% confidence interval, 0.45--0.89) per log(10) higher neutralization titre against HIV-1(MN), and the RRs of infection for second-, third-, and fourth-quartile responses of antibody blocking of gp120 binding to soluble CD4 versus first-quartile responses (the lowest responses) were 0.35, 0.28, and 0.22, respectively.

**Conclusions:** Despite inducing a complex, robust immune response, the vaccine was unable to reduce the incidence of HIV-1. Two interpretations of the correlative results are that the levels of antibodies (i) caused both an increased (low responders) and decreased (high responders) risk of HIV-1 acquisition or (ii) represented a correlate of susceptibility to HIV-1 but had no causal effect on susceptibility. Although the data cannot definitively discriminate between these 2 explanations, (ii) appears to be more likely.

*J Infect Dis* 2005;**191**(5):666--77.
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Smallpox vaccination does not elevate systemic levels of prothrombotic proteins associated with ischemic cardiac events {#cesec70}
=======================================================================================================================

**AUTHORS:** J.F. Shaklee, T.R. Talbot, J.A. Muldowney 3rd, D.E. Vaughan, J. Butler, F. House, J.E. Crowe Jr., L.H. Smith, K.M. Edwards

**Background:** During the recent smallpox vaccination campaigns, ischemic cardiac complications were observed after vaccination. To examine a possible association between the smallpox vaccine and postvaccination ischemic events, we investigated alterations in levels of prothrombotic proteins (plasminogen activator inhibitor type 1 \[PAI-1\] and soluble CD40 ligand \[sCD40L\]) in recently vaccinated individuals.

**Methods:** Vaccinia-naive (cohort N; aged 18--32 years) and vaccinia-experienced (cohort E; aged 33--49 years) healthy adults were vaccinated with a 1: 5 dilution of the Aventis Pasteur smallpox vaccine. Plasma levels of PAI-1 and sCD40L were measured in 30 subjects (cohort N, *n*=15; cohort E, *n*=15) at baseline and twice after vaccination (between days 7 and 9 and between days 26 and 30).

**Results:** Baseline mean PAI-1 levels significantly differed between cohorts N and E (*P*=.04). Within each exposure cohort, mean PAI-1 levels did not significantly change after vaccination. Baseline sCD40L levels did not differ between cohorts N and E. In cohort N, sCD40L levels significantly decreased after vaccination but returned to baseline levels within 1 month. Vaccination did not significantly alter levels of sCD40L in cohort E.

**Conclusions:** Levels of PAI-1 and sCD40L did not significantly increase after smallpox vaccination. Vaccine-induced alterations in levels of these prothrombotic proteins do not appear to play a role in ischemic events observed after smallpox vaccination.

*J Infect Dis* 2005;**191**(5):724--30.
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Development and duration of human papillomavirus lesions, after initial infection {#cesec80}
=================================================================================

**AUTHORS:** R.L. Winer, N.B. Kiviat, J.P. Hughes, D.E. Adam, S.K. Lee, J.M. Kuypers, L.A. Koutsky

**Background:** To determine the potential value of human papillomavirus (HPV) vaccines, information concerning the incidence and duration of clinically important lesions is needed.

**Methods:** A total of 603 female university students were followed for a mean duration of 38.8 months. Triannual gynecologic examinations included cervical and vulvovaginal specimen collection for Pap and HPV DNA testing. Women with cytologic evidence of a high-grade squamous intraepithelial lesion (SIL) were referred for colposcopically directed biopsy.

**Results:** Among women with incident HPV infection, the 36-month cumulative incidence of cervical SILs found by cytologic testing (47.2%; 95% confidence interval \[CI\], 38.9--56.4%) was higher than that of vaginal SILs (28.8%; 95% CI, 21.3--38.2%). The median time to clearance of cervical and vaginal SILs was 5.5 and 4.7 months, respectively. Among women with incident HPV-16 or HPV-18 infection, the 36-month cumulative incidence of cervical intraepithelial neoplasia (CIN) grade 2 was 20.0% (95% CI, 10.8--35.1%), and that of CIN grade 3 was 6.7% (95% CI, 2.5--17.0%). The 36-month cumulative incidence of clinically ascertained genital warts among women with incident HPV-6 or HPV-11 infection was 64.2% (95% CI, 50.7--77.4%).

**Conclusions:** Intraepithelial lesions are common early events among women with incident HPV infection, and the interval between incident HPV-16 or HPV-18 infection and biopsy-confirmed CIN grade 2--3 appears to be relatively short.

*J Infect Dis* 2005;**191**(5):731--8.
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Emerging infectious diseases: a 10-year perspective from the National Institute of Allergy and Infectious Diseases {#cesec90}
==================================================================================================================

**AUTHORS:** A.S. Fauci, N.A. Touchette, G.K. Folkers

Although optimists once imagined that serious infectious disease threats would by now be conquered, newly emerging (e.g. severe acute respiratory syndrome \[SARS\]), re-emerging (e.g. West Nile virus), and even deliberately disseminated infectious diseases (e.g. anthrax bio-terrorism) continue to appear throughout the world. Over the past decade, the global effort to identify and characterize infectious agents, decipher the underlying pathways by which they cause disease, and develop preventive measures and treatments for many of the world\'s most dangerous pathogens has resulted in considerable progress. Intramural and extramural investigators supported by the National Institute of Allergy and Infectious Diseases (NIAID) have contributed substantially to this effort. This overview highlights selected NIAID-sponsored research advances over the past decade, with a focus on progress in combating HIV/AIDS, malaria, tuberculosis, influenza, SARS, West Nile virus, and potential bio-terror agents. Many basic research discoveries have been translated into novel diagnostics, antiviral and antimicrobial compounds, and vaccines, often with extraordinary speed.

*Emerg Infect Dis* \[serial on the Internet\] 2005 Apr \[cited 29 March 2005\]. Available from: <http://www.cdc.gov/ncidod/eid/vol11no04/04-1167.htm>.

Recurring methicillin-resistant *Staphylococcus aureus* infections in a football team {#cesec100}
=====================================================================================

**AUTHORS:** D.M. Nguyen, L. Mascola, E. Bancroft

An outbreak of community-associated methicillin-resistant *Staphylococcus aureus* (MRSA) skin and soft tissue infection (SSTI) occurred in a college football team from August to September 2003. Eleven case-players were identified, and boils were the most common sign. Linemen had the highest attack rate (18%). Among 99 (93% of team) players with cultured specimens, 8 (8%) had positive MRSA nasal cultures. All available case-players\' MRSA isolates characterized had the community-associated pulsed-field type USA300. A case--control study found that sharing bars of soap and having pre-existing cuts or abrasions were associated with infection. A carrier--control study found that having a locker near a teammate with an SSTI, sharing towels, and living on campus were associated with nasal carriage. Successful outbreak control measures included daily hexachlorophene showers and hygiene education.

*Emerg Infect Dis* \[serial on the Internet\] 2005 Apr \[cited 29 March 2005\]. Available from: <http://www.cdc.gov/ncidod/eid/vol11no04/04-1094.htm>.

Epidemiology of *Escherichia coli* O157:H7 outbreaks, United States, 1982--2002 {#cesec110}
===============================================================================

**AUTHORS:** J.M. Rangel, P.H. Sparling, C. Crowe, P.M. Griffin, D.L. Swerdlow

*Escherichia coli* O157:H7 causes 73 000 illnesses in the United States annually. We reviewed *E. coli* O157 outbreaks reported to Centers for Disease Control and Prevention (CDC) to better understand the epidemiology of *E. coli* O157. *E. coli* O157 outbreaks (=2 cases of *E. coli* O157 infection with a common epidemiologic exposure) reported to CDC from 1982 to 2002 were reviewed. In that period, 49 states reported 350 outbreaks, representing 8598 cases, 1493 (17%) hospitalizations, 354 (4%) hemolytic uremic syndrome cases, and 40 (0.5%) deaths. Transmission route for 183 (52%) was foodborne, 74 (21%) unknown, 50 (14%) person-to-person, 31 (9%) waterborne, 11 (3%) animal contact, and 1 (0.3%) laboratory-related. The food vehicle for 75 (41%) foodborne outbreaks was ground beef, and for 38 (21%) outbreaks, produce.

*Emerg Infect Dis* \[serial on the Internet\] 2005 Apr \[cited 29 March 2005\]. Available from[: http://www.cdc.gov/ncidod/eid/vol11no04/04-0739.htm](http://www.cdc.gov/ncidod/eid/vol11no04/04-0739.htm){#interrefs30}.

Establishment of a universal size standard strain for use with the Pulsenet standardized pulsed-field gel electrophoresis protocols: converting the national databases to the new size standard {#cesec120}
===============================================================================================================================================================================================

**AUTHORS:** S.B. Hunter, P. Vauterin, M.A. Lambert-Fair, M.S. Van Duyne, K. Kubota, L. Graves, D. Wrigley, T. Barrett, E. Ribot

The PulseNet National Database, established by the Centers for Disease Control and Prevention in 1996, consists of pulsed-field gel electrophoresis (PFGE) patterns obtained from isolates of food-borne pathogens (currently *Escherichia coli* O157:H7, *Salmonella*, *Shigella*, and *Listeria*) and textual information about the isolates. Electronic images and accompanying text are submitted from over 60 US public health and food regulatory agency laboratories. The PFGE patterns are generated according to highly standardized PFGE protocols. Normalization and accurate comparison of gel images require the use of a well-characterized size standard in at least three lanes of each gel. Originally, a well-characterized strain of each organism was chosen as the reference standard for that particular database. The increasing number of databases, difficulty in identifying an organism-specific standard for each database, the increased range of band sizes generated by the use of additional restriction endonucleases, and the maintenance of many different organism-specific strains encouraged us to search for a more versatile and universal DNA size marker. A *Salmonella* serotype Braenderup strain (H9812) was chosen as the universal size standard. This strain was subjected to rigorous testing in our laboratories to ensure that it met the desired criteria, including coverage of a wide range of DNA fragment sizes, even distribution of bands, and stability of the PFGE pattern. The strategy used to convert and compare data generated by the new and old reference standards is described.

*J Clin Microbiol* 2005;**43**(3):1045--50.
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Characterization of rotavirus strains in a Danish population: high frequency of mixed infections and diversity within the VP4 gene of P\[8\] strains {#cesec130}
====================================================================================================================================================

**AUTHORS:** T.K. Fischer, J. Eugen-Olsen, A.G. Pedersen, K. Molbak, B. Bottiger, K. Rostgaard, N.M. Nielsen

We characterized the G and P types from 162 rotavirus-positive stool specimens collected from 162 persons in Denmark (134 children and 28 adults) with acute diarrhoea in 1998, 2000, and 2002. Samples were obtained during outpatient consultations (73%) and from hospitalized patients (27%). Although more than 20 different G--P combinations were identified, only 52% represented the globally most common types G1P\[8\], G2P\[4\], and G4P\[8\]. The G9 genotype, which is emerging worldwide, was identified in 12% of all samples. Twenty-one percent of the samples were of mixed genotypic origin, which is the highest frequency reported in any European population. The standard reverse transcription-PCR methods initially failed to identify a considerable fraction of the rotavirus P strains due to mutations at the VP4 primer-binding sites of P\[8\] strains. The application of a degenerate P\[8\] primer resulted in typing of most VP4 strains. There was considerable year-to-year variation among the circulating G--P types, and whereas G1P\[8\] was predominant in 1998 (42% of samples) and 2002 (26%), G2P\[4\] was the strain that was most frequently detected in 2000 (26% of samples). Our findings might implicate challenges for rotavirus vaccine implementation in a European population and underscore the importance of extensive strain surveillance prior to, during, and after introduction of any vaccine candidate.

*J Clin Microbiol* 2005;**43**(3):1099--104.
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Analysis of *Salmonella enterica* serotype typhi pulsed-field gel electrophoresis patterns associated with international travel {#cesec140}
===============================================================================================================================

**AUTHORS:** K. Kubota, T.J. Barrett, M.L. Ackers, P.S. Brachman, E.D. Mintz

Typhoid fever is a significant cause of morbidity and mortality worldwide, causing an estimated 16 million cases and 600 000 deaths annually. Although overall rates of the disease have dramatically decreased in the United States, the number of travel-related infections has increased in recent decades. Drug resistance among *Salmonella enterica* serotype typhi strains has emerged worldwide, making antimicrobial susceptibility testing an important function in public health laboratories. Pulsed-field gel electrophoresis (PFGE) subtyping of food-borne and waterborne pathogens has proven to be a valuable tool for the detection of outbreaks and laboratory-based surveillance. This retrospective study examined the distribution of PFGE patterns of *S. enterica* serotype typhi isolates from patients with a history of international travel. Isolates were collected as part of a passive laboratory-based antimicrobial susceptibility surveillance study. Isolates were PFGE subtyped by using the restriction enzyme XbaI to restrict the total genomic DNA. Isolates indistinguishable with XbaI were further characterized using the restriction enzyme BlnI. A total of 139 isolates were typed, representing travel to 31 countries. Restriction fragment patterns consisted of 14 to 18 fragments ranging in size from 580 to 40 kbp. Seventy-nine unique PFGE patterns were generated using XbaI. Isolates from the same geographic region did not necessarily have similar PFGE patterns. Of the 139 isolates, 46 (33%) were resistant to more than one antimicrobial agent (multidrug resistant \[MDR\]). Twenty-seven (59%) of 46 MDR isolates had indistinguishable PFGE patterns with both XbaI and BlnI. It appears that MDR *S. enterica* serotype typhi has emerged as a predominant clone in Southeast Asia and the Indian subcontinent.

*J Clin Microbiol* 2005;**43**(3):1205--9.
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